Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have ... Read More